Due to the critical role of angiogenesis in tumor biology, drug development over the past decades has focused on targeting this process, with VEGF identified as a primary therapeutic target for inhibiting angiogenesis and normalizing tumor vasculature [2,3]. This evidence concerns the gene VEGFA and neoplasm.